PedAM
Pediatric Disease Annotations & Medicines
| Disease | thromboembolism |
| Phenotype | C0011847|diabetes |
| Sentences | 8 |
| PubMedID- 26090400 | First, the aptt is affected by preanalytical (inappropriate collection, handling, and/or storage) and biological variables (lupus anticoagulant, hereditary or acquired factor deficiencies, hepatic insufficiency, vitamin k deficiency, disseminated intravascular coagulation, increased risk of thromboembolic events, hyperthyroidism, patients with diabetes, cancer, or myocardial infarction, and in pregnant women) [38, 39]. |
| PubMedID- 26152296 | When analyzed as a continuous variable, duration of diabetes mellitus was associated with risk of thromboembolism in a dose-response-dependent manner, but not with a higher risk of bleeding during anticoagulant treatment. |
| PubMedID- 25434631 | Aims: increasing evidence suggests an association between diabetes and risk of venous thromboembolism (vte); however, the results are inconsistent. |
| PubMedID- 24624928 | Since rivaroxaban inhibited the plasma-elicited ros generation and rage gene expression in huvecs, our present study suggests that blockade of the pathological crosstalk between the age-rage axis and thrombin-par-1 system by rivaroxaban might be a novel therapeutic strategy for reducing the risk of thromboembolic disorders in patients with diabetes [34]. |
| PubMedID- 23983579 | It can serve as a useful marker for the documentation of in vivo platelet activation, and thus, fore-warn the risk of thromboembolism in patients with diabetes mellitus, coronary syndromes, peripheral vascular diseases, and pre-eclampsia. |
| PubMedID- 22560173 | Venous thromboembolism in patients with diabetes mellitus. |
| PubMedID- 19896913 | In particular, maternal obesity is linked to numerous metabolic complications including subfertility, gestational diabetes, hypertensive disorders of pregnancy and thromboembolism with potential long-term health consequences for both mother and child. |
| PubMedID- 23457622 | Potential covariates were assessed based on known associations with ventricular size and heart disease, including demographics and anthropometric variables, as well as variables reflecting comorbidities and other characteristics (including systolic and diastolic blood pressure, hypertension, diabetes mellitus, history of venous thromboembolism, self-reported intentional exercise, use of anti-hypertensives, aspirin, statins, lipid-lowering therapy, hormone replacement therapy, hga1c, total cholesterol, low- and high-density lipoproteins, triglycerides, fasting glucose and insulin levels, serum il-6, c-reactive protein (crp), serum creatinine). |
Page: 1